| Gokden M, Mrak RE: Pituitary adenoma with craniopharyngioma component. Human Pathol, 40: 1189-1193, 2009 Gokden M, Al-Hinti JT, Harik SI: Peripheral nervous system pathology in fragile X ataxia/tremor syndrome (FXTAS). Neuropathology 29:280-284, 2009 Scheithauer BW, Erdogan S, Rodriguez F, Burger PC, Woodruff JM, Kros JM, Gokden M, Spinner RJ: Malignant peripheral nerve sheath tumors of cranial nerves and intracranial contents: A clinicopathologic study of 17 cases. Am J Surg Path,33:325-338, 2009 Gokden N, Gokden M, Phan D, McKenney J: The utility of Pax-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: An immunohistochemical study with comparison to renal cell carcinoma marker. Am J Surg Path 32: 1462-1467, 2008 Sahin FK, Koken G, Cosar E, Koken R, Sahin O, Gokden M: A prenatally diagnosed case of primitive neuroectodermal tumor. Fetal Diagn Ther 23: 267-270. 2008 Gokden M, Kemp SA, Gokden N: The utility of Pax-2 as an immunohistochemical marker for renal cell carcinoma in cytopathology. Diagn Cytopathol 36:473-477, 2008 Al-Mefty K, Pravdenkova S, Colli BO, Al-Mefty O, Gokden M: Chordoma and Chondrosarcoma: similar but with different skull base tumors. Cancer 110: 2457-2467, 2007 Gokden N. Greene GF. Bayer-Garner IB. Spencer HJ. Sanderson RD. Gokden M. Expression of CD138 (Syndecan-1) in renal cell carcinoma is reduced with increasing nuclear grade. Applied Immunohistochemistry & Molecular Morphology. 14(2):173-7, 2006 Cetin N. Dienel G. Gokden M. CD117 expression in glial tumors. Journal of Neuro-Oncology. 75(2):195-202, 2005 |